


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on May 15, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. BKR-107

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1632
Applicants : Dominique Lombardo, Eric Mas, Marie-Odile Sadoulet, Laurence Panicot-Dubois, Jean-Paul Bernard
Serial No. : 10/593,859
Filed : September 22, 2006
Conf. No. : 2965
For : Glycopeptides Derived From Pancreatic Structures, Antibodies and Applications Thereof in Diagnostics and Therapeutics

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. § 371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. In accordance with 37 C.F.R. § 1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschek, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/593,859
				Filing Date	September 22, 2006
				First Named Inventor	Dominique Lombardo
				Art Unit	1632
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	BKR-107

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
U1	US-				
U2	US-				
U3	US-				
U4	US-				
U5	US-				
U6	US-				
U7	US-				
U8	US-				
U9	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/M.N./	F1	WO 94/20610	09/15/2004	Aktiebolaget Astra	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	/Meera Natarajan/	Date Considered	08/11/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/593,859
Filing Date	September 22, 2006
First Named Inventor	Dominique Lombardo
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	BKR-107

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/M.N./	R1	LOMBARDO, D. "Bile Salt-Dependent Lipase: Its Pathophysiological Implications", <i>Biochimica et Biophysica Acta</i> , May 8, 2001, pp. 1-28, Vol. 1533.	
/M.N./	R2	MAS, E. et al. "The Oncofetal J28 Epitope Involves Fucosylated O-Linked Oligosaccharide Structures of the Fetoacinar Pancreatic Protein", <i>Glycobiology</i> , 1997, pp. 745-752, Vol. 7, No. 6.	
/M.N./	R3	PANICOT, L. et al. "The Formation of the Oncofetal J28 Glycotope Involves Core-2 β 6-N-Acetylglucosaminyltransferase and α 3/4-Fusosyltransferase Activities", <i>Glycobiology</i> , 1999, pp. 935-946, Vol. 9, No. 9.	
/M.N./	R4	REUE, K. et al. "cDNA Cloning of Carboxyl Ester Lipase from Human Pancreas Reveals a Unique Proline-Rich Repeat Unit", <i>Journal of Lipid Research</i> , 1991, pp. 267-276, Vol. 32.	
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	/Meera Natarajan/	Date Considered	08/11/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
0-PTO-9199 (1-800-786-9199) and select option 2.